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Aim: Evaluate the impact of the single nucleotide polymorphisms rs920778 and rs12826786 in the long
noncoding RNA HOTAIR in the susceptibility and prognosis of prostate cancer (PCa) patients. Patients
& methods: HOTAIR single nucleotide polymorphisms were genotyped by restriction fragment length
polymorphism in 151 PCa cases and 180 cancer-free controls. Odds ratio, 95% CIs and prognostic signifi-
cance were calculated. Results: Our data showed no statistically significant associations between HOTAIR
polymorphic variants in rs920778 and rs12826786 and PCa susceptibility. However, the CC genotype in
rs12826786 was significantly associated with shorter biochemical recurrence-free survival in pT3-stage PCa
patients. Conclusion: Our results indicate that HOTAIR rs12826786 CC genotype may be an independent
prognostic biomarker in a particular subset of PCa tumors.
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Prostate cancer (PCa) is the second most common malignancy diagnosed in men worldwide, and one of the major
causes of cancer-related morbidity and mortality [1]. Its classification is based on the Gleason grading system [2,3],
which takes into account the glandular architecture of the tumor and the tumor node metastasis staging system [4].
Ranging from clinically indolent to extremely aggressive tumors, PCa is known for its remarkable heterogeneity,
and is a challenge for clinicians to predict when a tumor will recur or progress, and which invasive cancers will
eventually metastasize and be fatal [5]. Few factors have been associated with increased PCa risk, and there are
only three well-established risk factors for the development of the disease: family history, ethnicity and age [6].
Additionally, genome-wide and replication association studies have shown that particular genetic variants in single
nucleotide polymorphisms (SNPs) may also be useful predictors of PCa risk [7].
Since the discovery that the human transcriptome is more complex than a collection of protein-coding genes and
their splice variants [8], it became crucial to understand the functions of nonprotein coding regions [9]. Among these
regions, long noncoding RNAs (lncRNA) represent spliced, polyadenylated and about 200 nucleotide-long RNAs,
which are crucial in physiological and pathologic conditions, including in cancer [10]. HOTAIR is a transacting
lncRNA whose aberrant expression has been associated with cancer patients’ overall survival, metastatic potential,
tumor recurrence and chemotherapy response in many tumor types [11–13]. Recently, HOTAIR has been suggested
to play an oncogenic role in PCa [14]. Additionally, its ability to bind and reduce androgen receptor degradation and
its enhanced transcriptional activity were shown to potentiate castration-resistant prostate cancer cell growth [15].
The relevance of particular HOTAIR genetic polymorphisms in cancer risk has been established in a variety of
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Table 1. Clinicopathologic features of prostate cancer patients and cancer-free controls.
Clinicopathologic feature Cases Controls
Number of cases 151 180
Age (years), mean ± SD 64.63 ± 5.33 53.07 ± 16.93
PSA (ng/ml), mean ± SD 8.9 ± 3.6 Not applicable
PSA grade, n (%) Not applicable
8 71 (47) Not applicable
≥8 to 15 66 (44) Not applicable
≥15 14 (9) Not applicable
Gleason score, n (%) Not applicable
7 (grade group 1)† 36 (24) Not applicable
=7 (grade groups 2 and 3)† 74 (49) Not applicable
7 (grade groups 4 and 5)† 41 (27) Not applicable
Pathological stage, n (%) Not applicable
pT2 65 (43) Not applicable
pT3 86 (57) Not applicable
†Grade groups, based on 2016 WHO classification of prostate tumors.
SD: Standard deviation.
tumor types, including colorectal [16], breast [17], esophageal [18], gastric [19] and brain [20] cancers. In particular,
variants in SNPs, rs920778 (located in an intronic enhancer) and rs12826786 (within the HOTAIR promoter),
functionally affect HOTAIR gene expression levels [18,19,21].
In the context of the emerging evidences for roles ofHOTAIR in prostate carcinogenesis [14,15], we evaluated how
these two functional HOTAIR SNPs may associate with PCa risk and patient prognosis in a Caucasian population.
Patients & methods
Study population
This case–control study comprised samples obtained from 151 PCa patients diagnosed at Portuguese Oncology
Institute – Porto, between 1999 and 2008. For controls, 180 cancer-free male individuals selected from blood
donors previously characterized for HOTAIR rs920778 and rs12826786 polymorphisms (130 cases) [20] and
from the Portuguese Oncology Institute (50 cases; healthy PCa-free individuals, confirmed with negative biopsy
results) were included. All participants were of Caucasian ethnic background. All patients enrolled in this study
were clinically stage I or II at diagnosis and were submitted to radical prostatectomy. Tumors were classified by
routine histopathological examination by an expert pathologist, and scored for Gleason [2,22] and pathological
staging [23]. The study was conducted according to institutional ethical standards, and all subjects provided signed
informed consent to participate in research studies (CES-IPOPFG-EPE 019/08). The clinicopathological data are
summarized in Table 1.
SNP genotyping
Genomic DNA was collected from peripheral blood leukocytes by proteinase K/phenol-chloroform/ethanol treat-
ment. In brief, samples were digested overnight at 55◦C in 300 μl of 10% sodium dodecyl sulfate and proteinase K
(20 mg/ml, 25 μl). The DNA from clinical samples was extracted by phenol-chloroform and ethanol precipitated.
DNA concentration and purity were determined using NanoDrop Lite Spectrophotometer (Nanodrop Technolo-
gies, Thermo Fisher, DE, USA).HOTAIR SNPs rs920778 (C>T) and rs12826786 (C>T) were genotyped through
PCR-based restriction fragment length polymorphism. Fifty nanograms of DNA were used for PCR amplification
with KAPA Taq DNA Polymerase (Kapa Biosystems, MA, USA). Primers sequences and PCR conditions were
previously described by us [20] and based on earlier publications [19,24]. PCR products were enzymatically digested at
37◦C for 5min with FastDigestMspI (Thermo Scientific,MA, USA) for rs920778, or 30min with FastDigest BglII
(Thermo Scientific) for rs12826786. Digestion products were resolved in 4% agarose gel stained with GreenSafe
Premium (NZYtech, Lisboa, Portugal).
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Table 2. Univariable analysis of association between rs920778 and rs12826786 polymorphisms and risk for each
prostate cancer group.
Polymorphism Control PCa OR (95% CI)† Gleason score >7
(grade groups 4 and 5)‡
OR (95% CI)† Pathological stage
pT3
OR (95% CI)†
rs920778
Genotypes
TT 81 78 – 21 – 43 –
CT 72 50 0.721 (0.448–1.161) 14 0.750 (0.355–1.583) 27 0.706 (0.397–1.257)
CC 27 23 0.885 (0.468–1.673) 6 0.857 (0.313–2.345) 16 1.116 (0.543–2.294)
CC + CT 99 73 0.766 (0.496–1.182) 20 0.779 (0.395–1.537) 43 0.818 (0.489–1.369)
Alleles
T 234 206 – 56 – 113 –
C 126 96 0.865 (0.625–1.198) 26 0.862 (0.516–1.440) 59 0.970 (0.662–1.421)
rs12826786
Genotypes
CC 88 85 – 22 – 48 –
CT 71 51 0.744 (0.466–1.187) 15 0.845 (0.408–1.748) 28 0.723 (0.412–1.267)
TT 21 15 0.739 (0.358–1.529) 4 0.762 (0.237–2.447) 10 0.873 (0.380–2.004)
TT + CT 92 66 0.743 (0.481–1.147) 19 0.826 (0.419–1.630) 38 0.757 (0.452–1.269)
Alleles
C 247 221 – 59 – 124 –
T 113 81 0.801 (0.571–1.124) 23 0.852 (0.501–1.449) 48 0.846 (0.567–1.263)
†OR with 95% CIs.
‡Grade groups, based on 2016 WHO classification of prostate tumors.
OR: Odds ratio; PCa: Prostate cancer.
Statistical analyses
Statistical analyses were performed using SPSS 22.0 (IBM SPSS Statistics, IBMR©, IL, USA). Allele and genotype
frequencies in PCa patients and cancer-free controls were compared by χ2 test, and nonparametric Wilcoxon–
Mann–Whitney test was used to compare age distribution between groups. Hardy–Weinberg equilibrium was
evaluated by χ2, comparing the expected and observed genotype frequencies of HOTAIR SNPs in the control
group. Odds ratio and 95% CIs were calculated by univariable and multivariable logistic regression (adjusted for
age as a continuous variable). The influence of HOTAIR genetic variants in PCa patients’ biochemical recurrence-
free survival (RFS) (defined as prostate-specific antigen [PSA] values >0.2 ng/ml following radical prostatectomy)
was illustrated with Kaplan–Meier survival curves, and the differences assessed by log-rank test (univariable) and
Cox regression (multivariable) model adjusted for patients’ age as a continuous variable, initial PSA and Gleason
grading (categorized in all cases using the recommendations of Epstein et al. [22], which has been then incorporated
in the 2016 WHO classification guidelines). Statistical significance was considered for p-values <0.05.
Results
HOTAIR & PCa risk
We analyzed 151 PCa patients and 180 cancer-free control males to study associations between variants in two
HOTAIR polymorphisms (rs920778 and rs12826786) and PCa susceptibility. The distribution of rs920778 and
rs12826786 allele frequencies in the control group was in Hardy–Weinberg equilibrium (p= 0.272 and p= 0.512,
respectively). A summary of the clinicopathologic features of controls and cases is shown in Table 1. The genotype
and allele frequencies of the rs920778 and rs12826786 polymorphisms in controls and PCa cases are shown in
Table 2. The frequencies of TT, CT and CC genotypes of rs920778 were 45.0, 40.0 and 15.0% in cancer-free
controls, and 51.7, 33.1 and 15.2% in PCa patients, respectively, indicating no statistically significant differences
(p > 0.05). In both groups, the T allele was the most frequent (65.0% in the control group and 68.2% in the
PCa samples). Regarding rs12826786 polymorphism, the frequencies of CC, CT and TT genotypes were 48.9,
39.4 and 11.7% in controls, and 56.3, 33.8 and 9.9% in PCa cases, respectively, again indicating no statistically
significant differences (p > 0.05). The C allele was the most frequent (68.6% in the control group and 73.2% in
PCa patients).
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Figure 1. Effect of HOTAIR rs920778 and rs12826786 genetic variants in the biochemical recurrence-free survival of pT3 prostate cancer
patients (n = 75). Kaplan–Meier curves illustrating biochemical recurrence-free survival defined by rs920778 (A) and rs12826786 (B)
genotypes. (A) No statistical differences were observed between patients harboring different genotypes of rs920778 (Log-rank test,
p-value = 0.116). (B) Patients harboring rs12826786 CC genotype (n = 40) have statistically significant shorter overall survival when
compared with patients with CT and TT genotype (n = 35; Log-rank test, p-value = 0.022). Tick marks indicate censored data.
Associations between the genotypes of HOTAIR rs920778 and rs12826786 and PCa susceptibility were first
estimated using univariable analyses. Regarding rs920778, the C allele was not significantly associated with risk for
PCa (Table 2). Similarly, genotypic analyses using TT as a reference (the most frequent genotype of the control
group) showed that none of the other genotypes (CC, CT or CC + CT) were significantly associated with risk
for PCa (Table 2). Regarding rs12826786, the T allele was not significantly associated with risk for PCa (Table 2).
Genotype analyses using CC genotype as a reference showed that TT, CT and combined TT + CT genotypes were
not significantly associated with increased risk for PCa (Table 2).
Similar analyses were done in the subset of PCa patients with more aggressive disease (two groups: Gleason
score >7 or pathological stage pT3) against the control group. In the same line as the whole PCa dataset, no
associations were observed in this subgroup of patients between rs920778 and rs12826786 alleles, or genotype
variants, and PCa risk (Table 2). These results suggest that HOTAIR rs920778 and rs12826786 variants do not
confer risk to develop PCa or specific subtypes of aggressive PCa (Gleason score >7 or pT3).
A multivariable logistic regression model adjusted for patient age as a continuous variable was also applied for
both polymorphisms. Consistent with the results observed in the univariable analysis, no associations between each
polymorphic variant and risk for developing PCa were found (data not shown). As expected, increased age was
found to be associated with increased risk for developing PCa (odds ratio: 1.070; 95% CI: 1.050–1.092).
Survival & prognostic value of HOTAIR SNPs
To understand the relevance of theseHOTAIR SNPs on the prognosis of PCa patients, we evaluated how rs920778
and rs12826786 genotypes associated with the progression-free survival (as assessed by biochemical recurrence)
in pT2 (n = 62) and pT3 (n = 75) stage PCa patients with available follow-up data. For pT2 patients, no
statistically significant associations were found (data not shown). Also, Kaplan–Meier curves with univariable log-
rank test (Figure 1) or multivariable Cox regression models (Table 3) showed no statistically significant associations
between rs920778 polymorphism and pT3 PCa patients’ biochemical RFS. In contrast, pT3 patients carrying the
CC genotype in rs12826786 (n = 40) showed statistically significant shorter biochemical RFS compared with
all other patients (CT + TT genotypes, n = 35), both in univariable (Figure 1B) (Log rank test, p = 0.022)
and in multivariable analyses adjusted for patient age, initial PSA and Gleason grading (Table 3) (Cox regression
model, p = 0.018), suggesting the C variant in rs12826786 as a negative and independent prognostic biomarker.
Strengthening our findings, the T allele seems to be associated with a good prognosis, as the TT genotype conferred
longer overall biochemical RFS comparing to CC (p = 0.040).
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Table 3. Multivariable Cox regression analysis of the association between rs920778 and rs12826786 polymorphisms and
biochemical recurrence-free survival for prostate cancer patients (pathological stage pT3).
Polymorphism Pathological Stage pT3 HR (95% CI)† p-value
rs920778 genotypes
TT 37 – –
CC 14 0.619 (0.236–1.625) 0.330
CT 24 0.553 (0.259–1.180) 0.126
CC + CT 38 0.573 (0.288–1.137) 0.111
Age 1.007 (0.945–1.073) 0.823
PSA grade
8
35 – –
≥8 to 15 30 0.938 (0.457–1.924) 0.861
≥15 10 1.149 (0.448–2.952) 0.772
ISUP/WHO grading system
1 7 – –
2 24 1.047 (0.283–3.874) 0.945
3 7 1.131 (0.241–5.320) 0.876
4 16 1.015 (0.242–4.258) 0.984
5 21 1.401 (0.387–5.076) 0.608
rs12826786 genotypes
CC 40 – –
TT 9 0.209 (0.047–0.933) 0.040
CT 26 0.490 (0.236–1.016) 0.055
TT + CT 35 0.422 (0.207–0.860) 0.018
Age 1.001 (0.938–1.069) 0.968
PSA grade
8 35 – –
≥8 to 15 30 0.945 (0.457–1.953) 0.879
≥15 10 1.225 (0.471–3.184) 0.677
ISUP/WHO grading system
1 7 – –
2 24 0.942 (0.253–3.508) 0.929
3 7 1.193 (0.253–5.640) 0.823
4 16 0.886 (0.209–3.758) 0.869
5 21 1.447 (0.399–5.242) 0.574
†HR with 95% CIs, adjusted for age (as a continuous variable), PSA and Gleason grading (categorized according to 2016WHO classification for prostate tumors). Bold-faced values indicate
significant differences at 5% level and p-value  0.05.
HR: Hazard ratio.
Discussion
SNPs represent themost frequent genetic variants among individuals, potentially affecting gene expression, function,
phenotypes and diseases [25]. The study of SNPs in cancer has been increasing concomitantly with the interest in
cancer genetic susceptibility. Particularly, SNPs in genes known to be implicated in carcinogenic processes have
been studied as they may affect susceptibility to several cancer types [26–28]. PCa is not an exception, and SNPs of
several genes have been studied and identified as putative biomarkers of susceptibility, including genes involved in
DNA repair pathways (XRCC4, PMSI, XRCC1 and XPD) [29,30] or growth pathways (VEGF, IGF1 and EGF) [30–32].
The role of the lncRNA HOTAIR in PCa has recently been addressed, which points it as a driver of tumor cell
growth, invasion/metastasis, androgen-independent androgen receptor activity and castration-resistant prostate
cancer progression [14,15,33]. The influence of three HOTAIR SNPs (rs12826786, rs1899663 and rs4759314) in
PCa pathophysiology was recently reported in an Iranian population [34]. In the context of the functional relevance
of rs920778 and rs12826786 SNPs regulating HOTAIR expression levels [18,19], we provide here the first study
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evaluating putative associations between these HOTAIR SNPs and PCa susceptibility and prognosis in a Caucasian
population.
Using univariable and multivariable statistical analyses, our data showed that rs920778 and rs12826786 are not
significantly associated with PCa susceptibility (neither in all PCa patients nor in the subset of more aggressive
Gleason score >7 or pathologic stage pT3 tumors). In accordance, it was previously showed that rs920778
does not influence gastric cancer susceptibility [35]. In contrast, in PCa, rs12826786 T allele was associated with
increased risks for benign prostate hyperplasia and PCa [34]. Additionally, other studies in esophageal squamous
cell carcinoma, gastric cancer [18,21], gastric cardia adenocarcinoma or breast cancer [17,19,36,37] suggested a role of
these polymorphisms in cancer susceptibility [17–19,21,36,37]. These observations are likely to reflect tumor-specific
carcinogenic processes that are not shared among these tumor types, and also due to ethnic differences among
studies. In fact, a recent meta-analysis showed that HOTAIR SNP rs920778 was associated with gastric cancer and
esophageal squamous cell carcinoma, but not with breast cancer, in Asians but not in Caucasians [38]. Nonetheless,
limitations in the sample size of our and others’ studies must not be ruled out, warranting further studies in larger
cohorts to validate these findings.
Interestingly, regarding the relevance of these HOTAIR SNPs on patient prognosis, we found that within the
subset of PCa patients with nonorgan-confined/locally advanced tumors (pT3), those carrying a CC genotype
in rs12826786 have significantly shorter biochemical RFS than those presenting CT or TT genotypes, both
in univariable and multivariable analyses. Of note, rs12826786 is located in the promoter region of HOTAIR
suggesting its variants may influence HOTAIR’s expression. Since expression of HOTAIR is a known biomarker of
poor prognosis in PCa [14,15], it is of relevance to study how variants of this SNP may induce differential expression
levels that can have biological roles in PCa. Furthermore, our results are of great clinical importance as they may
aid clinicians to timely identify PCa patients submitted to radical prostatectomy who are at increased risk of local
recurrence and disease progression, who might benefit from a closer follow-up or novel therapeutic strategies.
Conclusion
In conclusion, our findings suggest thatHOTAIR rs920778 and rs12826786 do not play amajor role in susceptibility
to PCa, while rs12826786 might have a prognostic value in locally advanced PCa (pT3 stage) patients. In the
future, further independent studies are required to validate our findings in larger datasets, as well as in patients of
different ethnic origins to further understand the relevance ofHOTAIR rs920778 and rs12826786 polymorphisms
in PCa pathophysiology.
Summary points
 The relevance of HOTAIR genetic variants in prostate cancer remains elusive.
 HOTAIR single nucleotide polymorphisms rs920778 and rs12826786 do not associate with prostate cancer risk.
 rs12826786 predicts shorter biochemical recurrence-free survival in pT3 patients.
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